IDEAYA Biosciences公司正在积极推进其候选药物Ide849针对Dll3上调实体瘤的全球一期临床试验。这一研发进展已通过美国证券交易委员会（SEC）的文件正式披露。
该试验旨在评估Ide849在Dll3表达上调的各类实体瘤患者中的安全性、耐受性及初步疗效。Dll3（Delta-like ligand 3）是Notch信号通路中的一个重要靶点，其在多种难治性实体瘤中异常高表达，使其成为颇具潜力的抗癌治疗靶标。
此次全球一期临床试验的推进，标志着IDEAYA Biosciences在精准肿瘤学领域的研究取得重要阶段性成果。公司将继续依托其深厚的靶向治疗研发平台，探索Ide849为特定患者群体提供新的治疗选择的可能性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.